Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome - Wikidata - wikimedia - TriplyDB

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

http://www.wikidata.org/entity/Q33935389

about

The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida Clinical perspectives on echinocandin resistance among Candida species Comparison of echinocandin antifungals Epidemiology of invasive candidiasis: a persistent public health problem In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Canadian clinical practice guidelines for invasive candidiasis in adults.FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.Candida parapsilosis, an emerging fungal pathogen Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies.Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Developments in the treatment of candidiasis: more choices and new challenges.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Micafungin: a new echinocandin antifungal.The pharmacology and clinical use of caspofungin.Nosocomial fungal infections: epidemiology, diagnosis, and treatment.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.Resistance to echinocandin-class antifungal drugs.Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure When primary antifungal therapy fails.In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen.Outcome of Candida Parapsilosis Complex Infections Treated with Caspofungin in Children.A single-centre 10-year experience with Candida bloodstream infections.Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.Current perspectives on echinocandin class drugs.Echinocandin pharmacodynamics: review and clinical implications.Antifungals to treat Candida albicans.Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.The evolving role of antifungal susceptibility testing.Mechanisms of Antifungal Drug Resistance.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Echinocandin Resistance in Candida Species: a Review of Recent Developments.Echinocandins in antifungal pharmacotherapy.

P2860

Q27026751-67F7934A-399F-4AB9-AF55-16C77CAD486E Q28082538-15286269-8872-4502-BC8E-F3B0056830B9 Q28273738-8FB97BF2-7CF7-4E39-937B-6FF2089C6613 Q29616758-677C9F4C-2440-44FC-A4AB-70CED23FB9A4 Q33876423-FB077F0C-2674-476A-85AA-0633074FB59C Q34237335-8E35F605-463A-4C48-9565-2A8738F95BF4 Q34737334-0B534B9E-399B-4775-907C-79160A095090 Q34852747-C1D390D8-5DAF-4ADA-9404-DB6BF728FAC7 Q34933267-35F465D8-3643-41E8-A547-BC41A2059B0E Q35129428-0F787903-80AB-477D-A5AC-9A2080C5741B Q35647785-E992A3EC-D167-4A43-9593-49EDE49BFA2E Q35666505-3409383E-28C3-495C-AC5F-39C603084BFB Q36172500-8B0504C2-0058-44B1-9692-9E3C20BCA83A Q36290758-3EC93A27-84A4-413C-897C-9CD362D0D63C Q36396614-A727BB97-F509-4E44-BC78-7FB3DCF3E9B4 Q36441524-DB45AA25-9F0B-4509-A6EC-D96CFA9D70BE Q36458402-426AA262-0277-4E3C-8E99-C6A85A355145 Q36623050-A9992C6C-B134-48AB-BE29-63F91690C2AF Q36626518-3F0E7318-2A78-4095-A14F-3BBC8090A3EF Q36693843-539BED8D-E33C-4B6F-8C97-EFCE90E46699 Q36788428-B74194E0-77B5-4042-9D02-11F81069B2EA Q36825717-F11F9721-7DE2-4786-B461-1759E9A00448 Q36845482-DFD415EC-3E15-4D61-922B-407413F86ECC Q36849595-42D22B76-EDCE-41AF-A6D0-BBB5F2A433DC Q36870777-70B1C55C-B262-4573-8F16-25DABAAE2B62 Q37036603-CC86F80B-AACB-4045-AF3C-058BECFBA71A Q37141191-6D295A61-3C90-4E41-8B3E-D075332D5BFA Q37160845-46A2846A-73C6-4289-8FF9-F2E053C447C7 Q37242216-3C063CCF-F81A-4838-982C-4AFE60355789 Q37252122-7DE4A8C5-5F03-4A88-88C5-5A53E4C7E910 Q37335848-9F032280-157D-4F22-AD16-C24D13C90CFC Q37554055-A214B3FE-DADF-4E4C-9217-2AFFA82572CF Q37718385-773E9C76-CF6B-446B-BD23-4F610362EFA7 Q37763928-8D6DDED3-ECEA-4181-A8D9-26FE70E068CF Q38027469-F5B0FD4B-F982-4135-A1A1-96784D381995 Q38095809-B4A68253-4B62-4238-924D-7C5A12035EEE Q38266675-B72EF294-BBF3-4879-A18B-8DAC53E26B67 Q38586680-4589538A-852A-4E0C-8522-00D78450D934 Q38988521-61FCF580-17ED-4C6F-BDC9-9A268B70D3B1 Q39458862-19FD1B32-A263-41A5-A133-81018877F820

P2860

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

http://www.wikidata.org/entity/Q33935389

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Caspofungin susceptibility tes ...... ip of MIC to treatment outcome

@ast

Caspofungin susceptibility tes ...... ip of MIC to treatment outcome

@en

type

label

Caspofungin susceptibility tes ...... ip of MIC to treatment outcome

@ast

Caspofungin susceptibility tes ...... ip of MIC to treatment outcome

@en

prefLabel

Caspofungin susceptibility tes ...... ip of MIC to treatment outcome

@ast

Caspofungin susceptibility tes ...... ip of MIC to treatment outcome

@en

P1433

Q33935389-CE5FE8B0-2354-4116-84F0-984FC9B99B3D

P1476

Q33935389-02890770-11CC-4B03-B733-5FFCE4D68728

P2093

Q33935389-12FF8C54-C234-42D7-B8E0-AB6D6D678C8F

Q33935389-174AE70C-FA87-4763-AC79-37CC61192240

Q33935389-1E333DC8-EFA9-4FD3-95DB-A39B1E9190C4

Q33935389-3A5A8483-39E8-4451-BA64-900FAD5DD3FD

Q33935389-53AD22AE-3C90-4585-88A7-8815D6090E52

Q33935389-9144CD9F-677D-4667-ADEF-74CBC393B7A9

Q33935389-9B5422C5-93AC-4896-978A-ACCB01EBF322

P2860

Q33935389-0E1451F9-BB55-4DA8-8B14-18B2B1BFE3F2

Q33935389-1998CF6B-9B1F-4FCC-A605-8956B462E427

Q33935389-2A5A0479-7BCD-4A91-AD87-F78FFF76E892

Q33935389-30BF12F6-BE68-4F75-9B37-5F94CC85A9A1

Q33935389-325E4A98-9EDC-4E0D-BBE7-64CD65CE324B

Q33935389-3287C036-8978-4DCD-91AF-D5FE9E082463

Q33935389-4D4F5D6D-B377-4AF5-916F-F29BFAC4885A

Q33935389-598B11F2-CFE7-4136-8C79-84BCF7EC70E1

Q33935389-5C30090C-B8F3-46A0-9F69-02FFB058ECC8

Q33935389-6A7EB9AE-1B16-4B6E-85C5-BA78FE910C2E

P304

Q33935389-D4F74BF6-678F-4051-AC9E-61CEAF06C4D5

P31

Q33935389-BE04A1A6-4BB4-4E7C-B0F8-2A6C78C6D7F8

P356

Q33935389-9D3B4D4C-926F-4C66-BC4D-1AF6A2BAD3A6

P407

Q33935389-6FA422B2-4E5A-41CB-A0AE-D6DC8A38FD26

P433

Q33935389-3D619D1D-CAF7-4C57-88FD-8D100E0BD198

P478

Q33935389-873B9815-882C-4627-AEE9-3FCA2DD57B5C

P577

Q33935389-2E2E6815-8038-47B1-A0F4-03923D31E044

P698

Q33935389-42E6FF98-CC89-43A6-B8C4-4232A7E3B2D0

P932

Q33935389-E768EC5A-ACBE-4902-B6F3-BA220EE09B50

P356

AAC.49.9.3616-3623.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Caspofungin susceptibility tes ...... ip of MIC to treatment outcome

@en

P2093

Carole Sable

http://www.w3.org/2001/XMLSchema#string

Chao-Min Hoe

http://www.w3.org/2001/XMLSchema#string

John Killar

http://www.w3.org/2001/XMLSchema#string

Kenneth Bartizal

http://www.w3.org/2001/XMLSchema#string

Lori Mixson

http://www.w3.org/2001/XMLSchema#string

Mary Motyl

http://www.w3.org/2001/XMLSchema#string

Nicholas Kartsonis

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species

In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates

In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species

Treatment of murine disseminated candidiasis with L-743,872

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

P304

3616-3623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.49.9.3616-3623.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16127030

http://www.w3.org/2001/XMLSchema#string

P932

1195423

http://www.w3.org/2001/XMLSchema#string